Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $9.1 million.

  • Veracyte's Change in Accured Expenses rose 4552500.0% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 101.27%. This contributed to the annual value of $3.5 million for FY2024, which is 62381.66% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's Change in Accured Expenses is $9.1 million, which was up 4552500.0% from $6.8 million recorded in Q2 2025.
  • Veracyte's 5-year Change in Accured Expenses high stood at $12.9 million for Q2 2024, and its period low was -$9.0 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $238000.0 (2021), whereas its average is $1.1 million.
  • In the last 5 years, Veracyte's Change in Accured Expenses plummeted by 187974.36% in 2023 and then surged by 4552500.0% in 2025.
  • Veracyte's Change in Accured Expenses (Quarter) stood at $11.1 million in 2021, then plummeted by 81.02% to $2.1 million in 2022, then grew by 29.34% to $2.7 million in 2023, then plummeted by 112.89% to -$351000.0 in 2024, then surged by 2699.72% to $9.1 million in 2025.
  • Its Change in Accured Expenses stands at $9.1 million for Q3 2025, versus $6.8 million for Q2 2025 and -$8.9 million for Q1 2025.